Coming Soon: GI Cancers (ASCO 2024)

Coming Soon: GI Cancers (ASCO 2024)

UPCOMING Join us forour roundtable in||latest advances in||your questions on||new therapies for||practice changes in||your patient cases in GI Cancers (ASCO 2024) Sara De Dosso ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND Thibaud Koessler Geneva University Hospitals,...
Biomarkers in GI & Lung

Biomarkers in GI & Lung

Biomarkers in GI & Lung The Significance of Biomarkers in GI Oncology for My Therapy Decision Sara De Dosso Biomarkers in GI Oncology: The Tests We Perform in Gastric and GEJ Today Rupert Langer Current Standards in in Lung Cancer Therapy: Which Biomarkers We...
Early NSCLC

Early NSCLC

Early NSCLC Welcome & introduction by host Isabelle Opitz Doing more with less: state of the art in tissue acquisition Carolin Steinack Current standards for pathology reporting in lung cancer Lukas Bubendorf Recent advances in thoracic surgery in lung cancer Brendon...
HER2 in Breast, Lung & GI Cancers

HER2 in Breast, Lung & GI Cancers

HER2 in Breast, Lung & GI Cancers Welcome & general introduction into HER2 testing Sabina Berezowska HER2 as a biomarker in breast cancer Zsuzsanna Varga Treatment considerations for HER2-positive GI-cancers Florian Lordick Clinical implications of HER2 in lung...
BRCA Mutated Tumors

BRCA Mutated Tumors

BRCA Mutated Tumors Welcome & introduction by host Berna Ă–zdemir BRCA as a biomarker: the who, when and how in BRCA testing Elena Guerini-Rocco Treatment considerations for BRCA mut. ovarian cancer Isabelle Ray-Coquard BRCA in prostate cancer: prognostic and...